I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original agreement |
Terms/Details (Date) |
ML Laboratories |
Maxygen Inc. (MAXY) |
Maxygen gained expanded rights to Ubiquitous Chromatin Opening Element technology |
Maxygen expanded its license from use in research to use in development of therapeutic proteins; terms were not disclosed (6/20) |
|
|||
Perfusion |
Cytomedix Inc. (AMEX:GTF) |
They settled a patent dispute over platelet- derived therapies for treating wounds and other damaged tissue |
Perfusion and affiliate Transcorporeal Inc. got a license to Cytomedix technology and will pay royalties of $250,000 and 10% of future sales (6/27) |
|
|||
II. TERMINATED AGREEMENTS | |||
XOMA Ltd. |
Zephyr Sciences Inc.* |
XOMA terminated a 2004 deal under which Zephyr gained rights to bactericidal/permeability-increasing protein-related products |
XOMA said Zephyr did not meet the financing requirements of the deal, which included the lead product Neuprex; the deal called for $11M in license fees and up to $62M in milestone payments, as well as royalties on any sales (7/15) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange; AMEX = American Stock Exchange | |||
